# Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD

> **NCT01391715** · PHASE3 · WITHDRAWN · sponsor: **Inje University**

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** rabeprazole
- **DRUG:** standard dose rabeprazole

## Key facts

- **NCT ID:** NCT01391715
- **Lead sponsor:** Inje University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** patients could not be recuited within study duration
- **Last updated:** 2012-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01391715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01391715, "Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01391715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*